ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data

On behalf of the Israel Lung Cancer Group (ILCG)

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data'. Together they form a unique fingerprint.

Medicine & Life Sciences